师资队伍

陈竺

院长

 

电话:
传真:
邮箱:
主页:

学习经历
1970-1975年 江西省信丰县、横峰县插队知青
1975-1977年 江西省上饶地区卫生学校医士专业学习
1978-1981年 上海第二医学院医疗系一部血液病学专业硕士研究生
1984-1989年 法国巴黎第七大学圣·路易医院血液中心实验室外籍住院医师,血液学研究所博士研究生、博士后

 

工作经历
1977-1978年 江西省上饶地区卫生学校内科教研组教师
1981-1984年 上海第二医学院附属瑞金医院内科住院医师
1989-1993年 上海第二医科大学(现上海交通大学医学院)附属瑞金医院内科主治医师,上海血液学研究所分子生物学实验室主任、研究员
1993-1995年 上海第二医科大学附属瑞金医院上海血液学研究所副所长(1995年当选为中国科学院院士)
1995-2000年 上海第二医科大学附属瑞金医院上海血液学研究所所长(2000年当选为发展中国家科学院院士)
2000-2007年 中国科学院副院长,上海第二医科大学附属瑞金医院上海血液学研究所所长(2003年当选为国际科学院协作组织主席、美国科学院外籍院士,2005年当选为法国科学院外籍院士,2005年起兼任上海交通大学系统生物医学研究院院长)
2007-2010年 卫生部部长
2010-2012年 卫生部部长,中华医学会会长
2012-2012年 农工党中央副主席,卫生部部长,中华医学会会长
2012-2013年 农工党中央主席,卫生部部长,中华医学会会长
2013-2014年 十二届全国人大常委会副委员长,农工党中央主席,中华医学会会长(2013年当选为英国皇家学会外籍会员)
2014-2015年 十二届全国人大常委会副委员长,农工党中央主席,欧美同学会(中国留学人员联谊会)会长,中华医学会会长
2015-2018年 十二届全国人大常委会副委员长,农工党中央主席,中国红十字会会长,欧美同学会(中国留学人员联谊会)会长
2018-    十三届全国人大常委会副委员长,农工党中央主席,中国红十字会会长,欧美同学会(中国留学人员联谊会)会长

 

 

1、白血病的细胞和分子机制研究
2、白血病基因产物靶向治疗
3、白血病系统生物学

[1] S. Xiao, D. Li, H. Q. Zhu, M. G. Song, X. R. Pan, P. M. Jia, L. L. Peng, A. X. Dou, G. Q. Chen, S. J. Chen, Z. Chen and J. H. Tong, RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins, Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 44, 2006, pp. 16448-16453.
[2] J. Hu, G. B. Zhou, Z. Y. Wang, S. J. Chen and Z. Chen, “Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: From acute promyelocytic leukemia to chronic myeloid leukemia and beyond,” In: G. F. VandeWoude and G. Klein, Eds., Advances in Cancer Research, Vol 98, 2007, pp. 191-220.
[3] L. H. Ma, H. Liu, H. Xiong, B. Chen, X. W. Zhang, Y. Y. Wang, H. Y. Le, Q. H. Huang, Q. H. Zhang, B. L. Li, Z. Chen and S. J. Chen, Aberrant transcriptional regulation of the MLL fusion partner EEN by AML1-ETO and its implication in leukemogenesis, Blood, Vol. 109, No. 2, 2007, pp. 769-777.
[4] G. B. Zhou, H. Kang, L. Wang, L. Gao, P. Liu, J. Xie, F. X. Zhang, X. Q. Weng, Z. X. Shen, J. Chen, L. J. Gu, M. Yan, D. E. Zhang, S. J. Chen, Z. Y. Wang and Z. Chen, Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo, Blood, Vol. 109, No. 8, 2007, pp. 3441-3450.
[5] H. Y. Le, Y. Zhang, H. Liu, L. H. Ma, Y. Jin, Q. H. Huang, Y. Chen, M. Deng, Z. Chen, S. J. Chen and T. X. Liu, eena promotes myeloid proliferation through stimulating ERK1/2 phosphorylation in zebrafish, Journal of Biological Chemistry, Vol. 283, No. 25, 2008, pp. 17652-17661.
[6] X. J. Sun, P. F. Xu, T. Zhou, M. Hu, C. T. Fu, Y. Zhang, Y. Jin, Y. Chen, S. J. Chen, Q. H. Huang, T. X. Liu and Z. Chen, Genome-Wide Survey and Developmental Expression Mapping of Zebrafish SET Domain-Containing Genes, Plos One, Vol. 3, No. 1, 2008.
[7] L. Wang, G. B. Zhou, P. Liu, J. H. Song, Y. Liang, X. J. Yan, F. Xu, B. S. Wang, J. H. Mao, Z. X. Shen, S. J. Chen and Z. Chen, Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia, Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 12, 2008, pp. 4826-4831.
[8] Z. Y. Wang and Z. Chen, Acute promyelocytic leukemia: from highly fatal to highly curable, Blood, Vol. 111, No. 5, 2008, pp. 2505-2515.
[9] N. N. Zhang, S. H. Shen, L. J. Jiang, W. Zhang, H. X. Zhang, Y. P. Sun, X. Y. Li, Q. H. Huang, B. X. Ge, S. J. Chen, Z. G. Wang, Z. Chen and J. Zhu, RIG-I plays a critical role in negatively regulating granulocytic proliferation, Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 30, 2008, pp. 10553-10558.
[10] S. J. Zhang, L. Y. Ma, Q. H. Huang, G. Li, B. W. Gu, X. D. Gao, J. Y. Shi, Y. Y. Wang, L. Gao, X. Cai, R. B. Ren, J. Zhu, Z. Chen and S. J. Chen, Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia, Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 6, 2008, pp. 2076-2081.
[11] Y. Zhang, X. T. Bai, K. Y. Zhu, Y. Jin, M. Deng, H. Y. Le, Y. F. Fu, Y. Chen, J. Zhu, A. T. Look, J. Kanki, Z. Chen, S. J. Chen and T. X. Liu, In vivo interstitial migration of primitive macrophages mediated by JNK-matrix metalloproteinase 13 signaling in response to acute injury, Journal of Immunology, Vol. 181, No. 3, 2008, pp. 2155-2164.
[12] J. Hu, Y. F. Liu, C. F. Wu, F. Xu, Z. X. Shen, Y. M. Zhu, J. M. Li, W. Tang, W. L. Zhao, W. Wu, H. P. Sun, Q. S. Chen, B. Chen, G. B. Zhou, A. Zelent, S. Waxman, Z. Y. Wang, S. J. Chen and Z. Chen, Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia, Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 9, 2009, pp. 3342-3347.
[13] H. D. Song, J. Liang, J. Y. Shi, S. X. Zhao, Z. Liu, J. J. Zhao, Y. D. Peng, G. Q. Gao, J. Tao, C. M. Pan, L. Shao, F. Cheng, Y. Wang, G. Y. Yuan, C. Xu, B. Han, W. Huang, X. Chu, Y. Chen, Y. Sheng, R. Y. Li, Q. Su, L. Gao, W. P. Jia, L. Jin, M. D. Chen, S. J. Chen, Z. Chen and J. L. Chen, Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves' disease, Human Molecular Genetics, Vol. 18, No. 6, 2009, pp. 1156-1170.
[14] Q. Y. Zhang, J. H. Mao, P. Liu, Q. H. Huang, J. Lu, Y. Y. Xie, L. Weng, Y. Zhang, Q. Chen, S. J. Chen and Z. Chen, A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia, Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 9, 2009, pp. 3378-3383.
[15] M. Hu, X. J. Sun, Y. L. Zhang, Y. Kuang, C. Q. Hu, W. L. Wu, S. H. Shen, T. T. Du, H. Li, F. He, H. S. Xiao, Z. G. Wang, T. X. Liu, H. Lu, Q. H. Huang, S. J. Chen and Z. Chen, Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling, Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 7, 2010, pp. 2956-2961.
[16] H. Wei, L. Dong, T. T. Wang, M. H. Zhang, W. Y. Hua, C. H. Zhang, X. Y. Pang, M. J. Chen, M. M. Su, Y. P. Qiu, M. M. Zhou, S. L. Yang, Z. Chen, M. Rantalainen, J. K. Nicholson, W. Jia, D. Z. Wu and L. P. Zhao, Structural shifts of gut microbiota as surrogate endpoints for monitoring host health changes induced by carcinogen exposure, Fems Microbiology Ecology, Vol. 73, No. 3, 2010, pp. 577-586.
[17] S. J. Chen, G. B. Zhou, X. W. Zhang, J. H. Mao, H. de The and Z. Chen, From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia, Blood, Vol. 117, No. 24, 2011, pp. 6425-6437.
[18] X. J. Yan, J. Xu, Z. H. Gu, C. M. Pan, G. Lu, Y. Shen, J. Y. Shi, Y. M. Zhu, L. Tang, X. W. Zhang, W. X. Liang, J. Q. Mi, H. D. Song, K. Q. Li, Z. Chen and S. J. Chen, Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia, Nature Genetics, Vol. 43, No. 4, 2011, pp. 309-U51.
[19] J. X. Liu, G. B. Zhou, S. J. Chen and Z. Chen, Arsenic compounds: revived ancient remedies in the fight against human malignancies, Current Opinion in Chemical Biology, Vol. 16, No. 1-2, 2012, pp. 92-98.
[20] J. H. Wang, W. L. Chen, T. L. Chen, Y. M. Zhu, W. N. Zhang, Y. Li, S. F. Wu, Y. P. Qiu, A. H. Zhao, J. M. Li, J. Q. Mi, J. Jin, Y. G. Wang, H. Huang, D. P. Wu, Y. Li, X. J. Yan, J. S. Yan, J. Y. Li, S. Wang, X. J. Huang, W. Jia, Z. Chen and S. J. Chen, Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia, Blood, Vol. 120, No. 21, 2012.
[21] T. Zhen, C. F. Wu, P. Liu, H. Y. Wu, G. B. Zhou, Y. Lu, J. X. Liu, Y. Liang, K. K. Li, Y. Y. Wang, Y. Y. Xie, M. M. He, H. M. Cao, W. N. Zhang, L. M. Chen, K. Petrie, S. J. Chen and Z. Chen, Targeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressor-Like Protein, Science Translational Medicine, Vol. 4, No. 127, 2012.
[22] Y. Shen, J. H. Wang, W. L. Chen, W. Jia, S. J. Chen and Z. Chen, Reply to Struys: Role of biomarker of 2-hydroxyglutarate in acute myeloid leukemia, Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 51, 2013, pp. E4940-E4940.
[23] J. H. Wang, W. L. Chen, J. M. Li, S. F. Wu, T. L. Chen, Y. M. Zhu, W. N. Zhang, Y. Li, Y. P. Qiu, A. H. Zhao, J. Q. Mi, J. Jin, Y. G. Wang, Q. L. Ma, H. Huang, D. P. Wu, Q. R. Wang, Y. Li, X. J. Yan, J. S. Yan, J. Y. Li, S. Wang, X. J. Huang, B. S. Wang, W. Jia, Y. Shen, Z. Chen and S. J. Chen, Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China, Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 42, 2013, pp. 17017-17022.
[24] Y. H. Wang, L. M. Zhang, W. L. Chen, J. H. Wang, N. Li, J. M. Li, J. Q. Mi, W. N. Zhang, Y. Li, S. F. Wu, J. Jin, Y. G. Wang, H. Huang, Z. Chen, S. J. Chen and H. R. Tang, Rapid Diagnosis and Prognosis of de novo Acute Myeloid Leukemia by Serum Metabonomic Analysis, Journal of Proteome Research, Vol. 12, No. 10, 2013, pp. 4393-4401.
[25] R. Xiao, X. D. Xi, Z. Chen, S. J. Chen and G. Y. Meng, Structural framework of c-Src activation by integrin beta 3, Blood, Vol. 121, No. 4, 2013, pp. 700-706.
[26] H. J. Zheng, W. B. Zhang, L. Zhang, Z. Z. Zhang, J. Li, G. Lu, Y. Q. Zhu, Y. Z. Wang, Y. Huang, J. Liu, H. Kang, J. Chen, L. J. Wang, A. J. Chen, S. T. Yu, Z. C. Gao, L. Jin, W. Y. Gu, Z. Q. Wang, L. Zhao, B. X. Shi, H. Wen, R. Y. Lin, M. K. Jones, B. Brejova, T. Vinar, G. P. Zhao, D. P. McManus, Z. Chen, Y. Zhou and S. Y. Wang, The genome of the hydatid tapeworm Echinococcus granulosus, Nature Genetics, Vol. 45, No. 10, 2013, pp. 1168-U302.
[27] W. L. Chen, J. H. Wang, A. H. Zhao, X. Xu, Y. H. Wang, T. L. Chen, J. M. Li, J. Q. Mi, Y. M. Zhu, Y. F. Liu, Y. Y. Wang, J. Jin, H. Huang, D. P. Wu, Y. Li, X. J. Yan, J. S. Yan, J. Y. Li, S. Wang, X. J. Huang, B. S. Wang, Z. Chen, S. J. Chen and W. Jia, A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value, Blood, Vol. 124, No. 10, 2014, pp. 1645-1654.
[28] J. Xu, Y. Y. Wang, Y. J. Dai, W. Zhang, W. N. Zhang, S. M. Xiong, Z. H. Gu, K. K. Wang, R. Zeng, Z. Chen and S. J. Chen, DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells, Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 7, 2014, pp. 2620-2625.
[29] L. Xu, Z. H. Gu, Y. Li, J. L. Zhang, C. K. Chang, C. M. Pan, J. Y. Shi, Y. Shen, B. Chen, Y. Y. Wang, L. Jiang, J. Lu, X. Xu, J. L. Tan, Y. Chen, S. Y. Wang, X. Li, Z. Chen and S. J. Chen, Genomic landscape of CD34(+) hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers, Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 23, 2014, pp. 8589-8594.
[30] Y. H. Liao, J. Y. Ling, G. Y. Zhang, F. J. Liu, S. C. Tao, Z. G. Han, S. J. Chen, Z. Chen and H. Y. Le, Cordycepin induces cell cycle arrest and apoptosis by inducing DNA damage and up-regulation of p53 in Leukemia cells, Cell Cycle, Vol. 14, No. 5, 2015, pp. 761-771.
[31] Y. Y. Xie, Y. L. Zhang, L. Jiang, M. M. Zhang, Z. W. Chen, D. Liu and Q. H. Huang, Disabled homolog 2 is required for migration and invasion of prostate cancer cells, Frontiers of Medicine, Vol. 9, No. 3, 2015, pp. 312-321.
[32] H. N. Zhang, L. N. Yang, J. Y. Ling, D. M. Czajkowsky, J. F. Wang, X. W. Zhang, Y. M. Zhou, F. Ge, M. K. Yang, Q. Xiong, S. J. Guo, H. Y. Le, S. F. Wu, W. Yan, B. Y. Liu, H. Zhu, Z. Chen and S. C. Tao, Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic, Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 49, 2015, pp. 15084-15089.
[33] Z. Q. Chen, H. N. Zhang, L. N. Yang, H. W. Jiang, S. J. Guo, Y. Li and S. C. Tao, Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901, Acta Biochimica Et Biophysica Sinica, Vol. 48, No. 5, 2016, pp. 474-481.
[34] Y. F. Liu, B. Y. Wang, W. N. Zhang, J. Y. Huang, B. S. Li, M. Zhang, L. Jiang, J. F. Li, M. J. Wang, Y. J. Dai, Z. G. Zhang, Q. Wang, J. Kong, B. Chen, Y. M. Zhu, X. Q. Weng, Z. X. Shen, J. M. Li, J. Wang, X. J. Yan, Y. Li, Y. M. Liang, L. Liu, X. Q. Chen, W. G. Zhang, J. S. Yan, J. D. Hu, S. H. Shen, J. Chen, L. J. Gu, D. Q. Pei, Y. J. Li, G. Wu, X. Zhou, R. B. Ren, C. Cheng, J. J. Yang, K. K. Wang, S. Y. Wang, J. H. Zhang, J. Q. Mi, C. H. Pui, J. Y. Tang, Z. Chen and S. J. Chen, Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia, Ebiomedicine, Vol. 8, 2016, pp. 173-183.
[35] S. T. Xu, S. S. Luo, H. Yao, H. Cai, X. M. Miao, F. Wu, D. H. Yang, X. M. Wu, W. J. Xie, H. Q. Yao, Z. S. Chen and J. Y. Xu, Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria, Journal of Medicinal Chemistry, Vol. 59, No. 10, 2016, pp. 5022-5034.
[36] Z. W. Xu, L. K. Huang, H. N. Zhang, Y. Li, S. J. Guo, N. Wang, S. H. Wang, Z. Q. Chen, J. F. Wang and S. C. Tao, PMD: A Resource for Archiving and Analyzing Protein Microarray data, Scientific Reports, Vol. 6, 2016.
[37] Y. J. Dai, Y. Y. Wang, J. Y. Huang, L. Xia, X. D. Shi, J. Xu, J. Lu, X. B. Su, Y. Yang, W. N. Zhang, P. P. Wang, S. F. Wu, T. Huang, J. Q. Mi, Z. G. Han, Z. Chen and S. J. Chen, Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement, Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 20, 2017, pp. 5237-5242.
[38] M. Sagner, A. McNeil, P. Puska, C. Auffray, N. D. Price, L. Hood, C. J. Lavie, Z. G. Han, Z. Chen, S. K. Brahmachari, B. S. McEuien, M. B. Soares, R. Balling, E. Epel and R. Arena, The P4 Health Spectrum - A Predictive, Preventive, Personalized and Participatory Continuum for Promoting Healthspan, Progress in Cardiovascular Diseases, Vol. 59, No. 5, 2017, pp. 506-521.
[39] Z. Q. Chen, T. Dodig-Crnkovic, J. M. Schwenk and S. C. Tao, Current applications of antibody microarrays, Clinical Proteomics, Vol. 15, 2018.
[40] P. R. Wang, S. Benhenda, H. Y. Wu, V. Lallemand-Breitenbach, T. Zhen, F. Jollivet, L. Peres, Y. W. Li, S. J. Chen, Z. Chen, H. de The and G. Y. Meng, RING tetramerization is required for nuclear body biogenesis and PML sumoylation (vol 9, 1277, 2018), Nature Communications, Vol. 9, 2018.
[41] P. R. Wang, S. Benhenda, H. Y. Wu, V. Lallemand-Breitenbach, T. Zhen, F. Jollivet, L. Peres, Y. W. Li, S. J. Chen, Z. Chen, H. de The and G. Y. Meng, RING tetramerization is required for nuclear body biogenesis and PML sumoylation, Nature Communications, Vol. 9, 2018.
[42] Y. L. Zhang, J. W. Sun, Y. Y. Xie, Y. Zhou, P. Liu, J. C. Song, C. H. Xu, L. Wang, D. Liu, A. N. Xu, Z. Chen, S. J. Chen, X. J. Sun and Q. H. Huang, Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation, Cell Research, Vol. 28, No. 4, 2018, pp. 476-490.

Copyright © 2016 上海交大系统生物医学研究院 版权所有
分享到

地址:上海市东川路800号
邮编:200240
电话:021-34206059